Department of Dermatology, Mayo Clinic, Scottsdale, Arizona; Case Western Reserve University School of Medicine, Cleveland, Ohio.
Department of Dermatology, Mayo Clinic, Scottsdale, Arizona.
J Am Acad Dermatol. 2019 Mar;80(3):626-632.e1. doi: 10.1016/j.jaad.2018.10.018. Epub 2018 Oct 22.
Inositol polyphosphate 5-phosphatase (INPP5A) has been shown to play a role in development and progression of cutaneous squamous cell carcinoma (cSCC). The goal of the current study was to explore the prognostic value of INPP5A expression in cSCC.
A total of 189 cases of actinic keratosis and SCC in 174 patients were identified; clinical and outcome data were abstracted, histopathology was rereviewed, and immunohistochemical staining and interpretation was performed for INPP5A.
The majority of tumors (89.4%) had an INPP5A score of 2 or 3. No patients had complete loss of INPP5A. Tumors with an INPP5A score of 1 were more likely to be intermediate- to high-risk tumors (Brigham and Women's Hospital stage ≥T2a 85.0% vs 23.7% [P < .0001]) characterized by a larger diameter (2.4 cm vs 1.3 cm [P = .0004]), moderate-to-poor differentiation (86.7% vs 17.6% [P < .0001]), and perineural invasion (37.5% vs 5.3%, [P < .0001]). An INPP5A score of 1 was associated with a worse 3-year survival (a rate of 42.3% [hazard ratio, 2.81, P = .0006]) and a local metastasis rate of 48.0% (hazard ratio, 4.71; P < .0001).
Low INPP5A scores are predictive of aggressive tumors and may be a useful adjunct to guide clinical management of cSCC.
已证实肌醇多磷酸 5-磷酸酶(INPP5A)在皮肤鳞状细胞癌(cSCC)的发生和进展中发挥作用。本研究旨在探讨 INPP5A 表达在 cSCC 中的预后价值。
共纳入 174 例患者的 189 例光化性角化病和 SCC 病例;提取临床和结局数据,重新复习组织病理学,进行 INPP5A 的免疫组织化学染色和解读。
大多数肿瘤(89.4%)的 INPP5A 评分为 2 或 3。没有患者完全缺失 INPP5A。INPP5A 评分为 1 的肿瘤更可能为中高危肿瘤(布莱根妇女医院分期≥T2a 为 85.0%比 23.7%[P<.0001]),表现为更大的直径(2.4cm 比 1.3cm[P=.0004])、中-低分化(86.7%比 17.6%[P<.0001])和神经周围侵犯(37.5%比 5.3%[P<.0001])。INPP5A 评分 1 与较差的 3 年生存率(42.3%[风险比,2.81,P=.0006])和局部转移率 48.0%(风险比,4.71;P<.0001)相关。
低 INPP5A 评分提示侵袭性肿瘤,可能是指导 cSCC 临床管理的有用辅助手段。